Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Academisch Medisch Centrum, Amsterdam

University of Rochester, Rochester

Fox Chase Cancer Center, Philadelphia

Duke University, Durham

Emory University, Atlanta

University of Miami, Miami

Moffitt Cancer Center, Tampa

CHU de Montpellier, Montpellier

CHU de Rennes, Rennes

Hospital Universitario de Salamanca, Salamanca

Sarah Cannon - Tenessee, Nashville

Vanderbilt University, Nashville

Ohio State University, Columbus

Hopital Haut-Leveque, Pessac

Cleveland Clinic - Taussig Cancer Institute, Cleveland

Karmanos Cancer Institute, Detroit

Johannes Gutenberg University Hospital-University Mainz, Mainz

Advocate Aurora Health - Advocate Lutheran General Hospital, Park Ridge

Loyola University Medical Center, Maywood

University of Chicago, Chicago

Centre Hospitalier Lyon Sud, Pierre-Bénite

Hospital Saint Louis, Paris

Baylor Cancer Hospital, Dallas

MD Anderson Cancer Center, Houston

Sarah Cannon- Denver, Denver

Munich University of Technology-Medical Faculty- Ethics Committee, München

Banner MD Anderson Cancer Center, Gilbert

University California Los Angeles (UCLA), Santa Monica

Stanford University, Palo Alto

Universitaetsklinikum Wuerzburg, Würzburg

Swedish Cancer Institute, Seattle

Dana Farber Cancer Institute, Boston

Hackensack University Medical Center, Hackensack

University Medical Center Groningen, Groningen

Erasmus MC, Rotterdam

Hospital Universitari Vall D'Hebron, Barcelona

Hospital Clinic Barcelona, Barcelona

Queen Elizabeth University Hospital, Glasgow

Kings College Hospital, London

Manchester Royal Infirmary, Manchester